Login to Your Account



Assembly Biosciences poised to get up to $2.78B from Allergan in microbiome deal

By Michael Fitzhugh
Staff Writer

Tuesday, January 10, 2017

Exclusive rights to Assembly Biosciences Inc.'s preclinical GI microbiome programs and additional GI programs secured with a $50 million up-front from Allergan plc could yield a much bigger payday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription